Adding Weekly GLP-1 to Cognitive Behavioral Therapy Further Reduces Heavy Drinking

Follow Drugslib on

April 30, 2026 -- A team of National Institutes of Health (NIH) scientists and international colleagues have reported the first evidence from a randomized controlled clinical trial indicating that a GLP-1 receptor agonist can reduce the days in which patients with obesity and alcohol use disorder engage in heavy drinking. Led by researchers at Copenhagen University Hospital, the new study adds to a growing body of evidence suggesting that GLP-1s could be useful in treating alcohol use disorder.

  • Clinical trial suggests semaglutide may help patients with alcohol use disorder and obesity.

    • “Very few medications are currently approved for alcohol use disorder, and these are vastly underutilized. A new option that is more accessible and more effective could be a gamechanger for closing the treatment gap,” said Director of NIH’s National Institute on Alcohol Abuse and Alcoholism (NIAAA) George Koob, Ph.D., a study co-author.

    Research has increasingly suggested that GLP-1s approved for weight loss may benefit those with substance use disorders. While one recent clinical trial found that a GLP-1 had no effect on the heavy drinking of study participants as a whole group, a subset who had obesity responded strongly.

    The authors of the new study specifically enrolled 108 treatment-seeking patients with alcohol use disorder and comorbid obesity. In addition to standard cognitive behavioral therapy, participants received either a placebo or a dose of semaglutide on a weekly basis for 26 weeks. Throughout the trial, the researchers collected self-reported drinking data as well as measurements of several quantitative biomarkers.

    They found that participants receiving semaglutide experienced a 41.1% reduction in heavy drinking days, a 13.7% greater reduction than that of the placebo group. Measurements of blood-alcohol biomarkers supported the self-reported-data-based findings. As expected, the researchers saw that decreases in bodyweight, blood pressure, and other clinical measures were more pronounced in the GLP-1 group. The authors took note of some adverse effects, including gastrointestinal symptoms, though they were transient and mild.

    The researchers also found that semaglutide could potentially lead to positive outcomes more often than other medications for alcohol use disorder, as its number needed to treat (NNT) — a metric of clinical efficacy — in this study was 4.3, while the NNT of approved medications is 7 or higher.

    “We’re beginning to see some of that potential for GLP-1s to treat drug addiction turn into reality. Questions remain but this is nonetheless very encouraging,” said Director of NIH’s National Institute on Drug Abuse (NIDA) and study co-author Nora Volkow, M.D.

    Next, the authors would like to examine the effects of GLP-1s over a longer duration and in a larger population to confirm their findings here.

    The scientific team was led by first author Mette Kruse Klausen, M.D., and corresponding author Anders Fink-Jensen, D.M.Sc., at Copenhagen University Hospital.

    About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

    NIH…Turning Discovery Into Health®

    Reference

    Mette Kruse Klausen et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. The Lancet. 2026. DOI: 10.1016/S0140-6736(26)00305-3

    Source: NIH

    Source: HealthDay

    Related articles

  • Novo Nordisk Introduces Ozempic Pill; Available in the US Q2 2026 - February 4, 2026
  • FDA Approves Ozempic (semaglutide) as the Only GLP-1 RA to Reduce the Risk of Worsening Kidney Disease and Cardiovascular Death in Adults with Type 2 Diabetes and Chronic Kidney Disease - January 28, 2025
  • Novo Nordisk Receives FDA Approval of Higher-Dose Ozempic 2 mg Providing Increased Glycemic Control for Adults with Type 2 Diabetes - March 28, 2022
  • FDA Approves Ozempic (semaglutide) for Cardiovascular Risk Reduction in Adults with Type 2 Diabetes and Known Heart Disease - January 16, 2020
  • Novo Nordisk Receives FDA Approval of Ozempic (semaglutide) Injection For the Treatment of Adults with Type 2 Diabetes - December 5, 2017
  • Novo Nordisk Receives Positive 16-0 vote from FDA Advisory Committee in Favor of Approval for Semaglutide - October 18, 2017
  • Novo Nordisk Files for Regulatory Approval of Once-Weekly Semaglutide with the FDA for the Treatment of Type 2 Diabetes - December 5, 2016

    • Ozempic (semaglutide) FDA Approval History

    More news resources

  • FDA Medwatch Drug Alerts
  • Daily MedNews
  • News for Health Professionals
  • New Drug Approvals
  • New Drug Applications
  • Clinical Trial Results
  • Generic Drug Approvals
  • Drugs.com Podcast

    • Subscribe to our newsletter

    Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

    Posted : 2026-05-02 14:26

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords